Emergency Use Authorization Request for Ensovibep Submitted to the US Food and Drug Administration for the Treatment of COVID-19
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, was informed by its partner Novartis that the company has requested Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for ensovibep, a DARPin antiviral therapeutic candidate to treat COVID-19.
This Submission is Based on the Totality of the Data From Clínical and Preclinical Studies Including the Positive Results of the Phase II Portion of the EMPATHY Study, a Randomized, Placebo-Controlled Study Which Enrolled 407 Symptomatic Patients Infected with SARS-Cov-2. ...
